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eﬁ  ning and classifying disease 
is at the heart of medical 
practice. But the standard 
approach to classiﬁ  cation is slow and 
laborious. A new approach promises 
to revolutionise the way in which we 
classify disease. It involves the free and 
public sharing of information via the 
Internet—the so-called open-source, or, 
perhaps more appropriately termed, 
“free community,” approach (R. M. 
Stallman, personal communication). 
The International Society for 
Neuropathology is the ﬁ  rst worldwide 
professional medical organisation 
to adopt such an approach with its 
International Classiﬁ  cation of Diseases 
of the Nervous System (ICDNS; see 
http:⁄⁄www.ICDNS.org). The main 
characteristics of the ICDNS are free 
collaboration via the Internet, online 
access to all collaborative tools via the 
World Wide Web, global participation, 
and democratic decision making [1].
Why We Need a New Approach
Before a disease can be recognised, its 
nature and the conditions surrounding 
it must be determined in order to 
establish criteria for its deﬁ  nition. The 
more precise a disease deﬁ  nition, the 
greater the beneﬁ  t is for the patient, 
especially where speciﬁ  c treatments are 
available. Once individual diseases are 
deﬁ  ned, they can be classiﬁ  ed, resulting 
in the creation of conceptual links 
that are fundamentally important for 
medical practice and the advancement 
of medical knowledge. One example 
is the conceptual linking of Pick 
disease, Alzheimer disease, progressive 
supranuclear palsy, and corticobasal 
degeneration as members of the group 
of tauopathies. However, the way in 
which medical classiﬁ  cations of disease 
traditionally evolve is problematic. 
Usually, small groups of experts 
meet and decide on a classiﬁ  cation 
that ﬁ  ts best with their personal 
experience. Classiﬁ  cations then change 
when new scientiﬁ  c developments are 
applied to link or separate different 
conditions. An example is the 
identiﬁ  cation of several pathologically 
distinct types of frontotemporal 
dementia based on the application 
of immunohistochemical staining for 
tau protein and ubiquitin. The wider 
medical community subsequently 
validates these new schemes, provided 
there is agreement on the basic aspects 
of any new taxonomic concept. Often, 
however, consensus only emerges 
after many years and even decades of 
controversy and dispute. The World 
Health Organization’s classiﬁ  cation of 
brain tumours [2] is an example of a 
classiﬁ  cation that has taken decades to 
mature. Thus, the established process 
is not very effective and is undoubtedly 
time consuming. It is also occasionally 
politicised, as “egos” may be unable 
to resist the temptation of leaving 
their personal mark, while ignoring 
the cultural beneﬁ  t of consensus 
agreement that results in knowledge 
that is usable by everyone.
New disease entities are presently 
emerging at a much higher rate 
because of advances in biomedicine 
that were triggered by the Human 
Genome Project. More and more 
diseases are being redeﬁ  ned according 
to molecular criteria. The Lewy body 
diseases, which share a pathological 
aggregation of the protein alpha-
synuclein (“alpha-synucleinopathies”), 
are an example of a disease subset 
now deﬁ  ned by a common molecular 
pathology. The large ﬁ  eld of pathology 
and the neurosciences are two areas 
where the translation of morphological 
phenotypes into molecularly deﬁ  ned 
entities is already well underway. With 
the pace of change accelerated by 
advances in molecular science, we 
need a much more effective way to 
develop the debate about medical 
classiﬁ  cations. 
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Box 1. The Open Source 
Initiative
“The basic idea behind open source 
is very simple: When programmers can 
read, redistribute, and modify the source 
code for a piece of software, the software 
evolves. People improve it, people adapt 
it, people ﬁ  x bugs. And this can happen 
at a speed that, if one is used to the 
slow pace of conventional software 
development, seems astonishing… 
Open source software is an idea whose 
time has ﬁ  nally come. For twenty years 
it has been building momentum in the 
technical cultures that built the Internet 
and the World Wide Web. Now it is 
breaking out into the commercial world, 
and that’s changing all the rules.” 
(It should be noted that the Open 
Source Software Initiative of 1998 was 
preceded by Richard Stallman’s Free 
Software Movement of 1983 [5].)
Source: Open Source Web site (http://
www.opensource.org).
Open access, freely available online
The Health in Action section is a forum for individuals 
or organizations to highlight their innovative 
approaches to a particular health problem.PLoS Medicine  |  www.plosmedicine.org 114
Open Source and the ICDNS
One effective way to further develop 
this debate is to adopt the approach 
used by the free-software and open-
source movements [3], which have 
spawned free software, free operating 
systems, and free scientiﬁ  c and medical 
journals. Open source has profoundly 
important implications for science, 
technology, and medicine. 
The development of global computer 
networks and the World Wide Web, 
in particular, have fostered the 
evolution of free and global sharing of 
intellectual property. The Open Source 
Initiative (http:⁄⁄www.opensource.
org) is a nonproﬁ  t venture dedicated 
to managing and promoting the open-
source idea (Box 1). A related but 
more radical concept is propagated 
by the Free (as in freedom) Software 
Foundation (http:⁄⁄www.fsf.org). The 
creation of the GNU/Linux operating 
system (http:⁄⁄www.gnu.org and 
http:⁄⁄www.linux.org) has resulted 
from the work of both.
The ICDNS was inspired by the free 
software and open-source approach to 
software development. The Council 
of the International Society for 
Neuropathology approved the ICDNS 
as a community activity at its last 
meeting in Turin, Italy, in September 
of 2003 [4]. The implications of ICDNS 
go far beyond deﬁ  ning neurological 
diseases. The beneﬁ  ts include the 
standardisation of neuropathological 
training programmes across continents 
and a new means of direct, professional 
communication between colleagues 
from countries all over the globe.
How ICDNS Works
Diagnostic criteria for all recognised 
neuropathological diseases are being 
published on the Web at http:⁄⁄www.
ICDNS.org, where the global 
community of neuropathologists can 
judge them (Figure 1). No named 
individual or national group is leading 
the initiative. Existing classiﬁ  cations 
are translated into a generic 
format, avoiding personal as well as 
institutional names to ensure consistent 
terminology between related disease 
processes. 
Although still in its early days, 
deﬁ  nitions for Lewy body disease,  
Alzheimer disease, and several 
tumours are now online. Individual 
ICDNS members (membership is 
free) as well as expert interest groups 
propose core deﬁ  nitions, which 
are then posted so that the global 
consultation process begins via the 
World Wide Web. After an online 
discussion period, ICDNS members 
holding a specialist certiﬁ  cation in 
diagnostic neuropathology are invited 
to vote. Comments made online by 
contributors become part of the history 
of a disease deﬁ  nition so that nobody 
is left out and divergent views are not 
forgotten. The discussion process is 
thereby open and democratic, allowing 
wide participation—including from 
individuals in developing countries 
who are often excluded in traditional 
academic discussions.
Different countries around the 
world show variations in their use 
of diagnostic criteria and medical 
classiﬁ  cations, which, in turn, can lead 
to different treatment approaches. 
This can certainly create problems 
when trying to reach a global 
consensus. However, free access to the 
information held under the ICDNS 
open licence may help to minimise 
these problems by promoting and 
stimulating collaborative research and 
the exchange of scientiﬁ  c ideas across 
the globe. 
Certain diseases are far more 
common in particular parts of 
the world. In India, for example, 
neurotuberculosis, cerebral malaria, 
fungal infections of the central 
nervous system, human rabies, 
encephalomyelitis, and cerebrovenous 
thrombosis are more common than 
in most developed countries. While 
the conventional pathology of these 
diseases is well known—and in some 
cases we also have expert knowledge on 
their morphological phenotypes—their 
exact pathogenesis is not understood, 
and cellular as well as molecular 
knowledge is missing. The ICDNS is 
expected to stimulate local researchers 
to engage in collaborative international 
projects in which they can receive 
feedback via the global consultation 
process. 
Publication of ICDNS criteria 
occurs under a general public licence. 
This means that all text can be 
freely downloaded and republished, 
avoiding the need for deﬁ  ning basic 
facts over and over again. Both core 
deﬁ  nitions and comments may be used 
immediately for diagnostic purposes as 
outlined in the guidance section of the 
ICDNS Web site.
Future Directions
In the future, deﬁ  nitions of 
histopathological phenotypes may be 
linked to clinical as well as molecular 
biological datasets, such as those 
obtained from microarrays and 
combined with imaging parameters. 
It is obvious that expert consensus on 
histological phenotypes is required 
before “genome matching” and similar 
procedures can be applied to complex 
diseases in a meaningful way. Most 
diseases are presently still deﬁ  ned 
on the basis of their histopathology. 
Online forums to ﬁ  nd diagnostic 
consensus will provide a very effective 
means of correlating descriptive data 
with molecular data. Subsequently, 
statistical clusters representing 
“signatures of disease” may be extracted 
from multidimensional data spaces 
that will be available online. This opens 
new roads to link with diagnostic and 
therapeutic approaches.
It seems reasonable to propose 
that the adoption of the ICDNS 
paradigm by other medical specialties 
would facilitate the development 
of a comprehensive, global body 
of medical knowledge. Free access 
to this knowledge would allow 
novel, collaborative approaches to 
be developed to address the most 
pressing medical problems through 
supranational concerted efforts. The 
rather lowly role traditionally ascribed 
to the exercise of deﬁ  ning and 
classifying diseases would give way to 
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Figure 1. Pilocytic Astrocytoma 
Future brain tumour classiﬁ  cations 
will be decided in a democratic way. 
(Photo: Dr. F. Roncaroli, Department 
of Neuropathology, Imperial College 
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an appreciation for the key importance 
of this process as a potentially powerful 
driver of change.  
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